{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:40:09Z","timestamp":1792010409203,"version":"4.4.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["54767414GLN2001"],"award-info":[{"award-number":["54767414GLN2001"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Significance Statement<\/jats:title>\n                    <jats:p>Treatment of proliferative GN with monoclonal Ig deposition (PGNMID), in which direct deposition of the monoclonal proteins damages the kidney, is not established. Daratumumab, a monoclonal anti-CD38 antibody, has shown effectiveness as multiple myeloma therapy. In an open-label, phase 2 study, the authors evaluated safety and efficacy of a 6-month course of intravenous daratumumab in 11 patients with PGNMID and one with C3 glomerulopathy with monoclonal gammopathy. Five episodes of serious adverse events (two of which were infection related) occurred. All ten patients with PGNMID who received at least one daratumumab dose experienced a significant reduction in proteinuria at 6 months, which was sustained in seven patients by 12 months. Overall, in this pilot study, daratumumab\u2019s acceptable toxicity profile and significant improvement in proteinuria, while stabilizing kidney function, suggest further investigation is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment of proliferative GN with monoclonal Ig deposits (PGNMID) is not established. A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma. Abnormal plasma cell clones may play a role in the pathogenesis of PGNMID.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated daratumumab\u2019s safety and efficacy in an open-label, phase 2 trial in 11 adults with PGNMID and one with C3 glomerulopathy (C3G) with monoclonal gammopathy. Patients had an eGFR &gt;20 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      and proteinuria &gt;1 g\/d. They received daratumumab intravenously (16 mg\/kg) once weekly for 8 weeks, and then every other week for eight additional doses. Primary outcome was safety, defined as major infections, grade 3 or 4 anemia, leukopenia, or thrombocytopenia. Secondary outcomes were rate of complete remission (proteinuria &lt;500 mg\/d with &lt;15% decline in baseline eGFR) or partial remission (&gt;50% reduction in 24-hour proteinuria with &lt;30% decline in eGFR) and proteinuria at 6 and 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One patient with C3G had GN unrelated to the monoclonal gammopathy, and one with PGNMID did not complete the first infusion. Five serious adverse events occurred. During the 12 months of the trial, six of the ten patients with PGNMID who received at least one dose of daratumumab had a partial response, and four had a complete response (an overall response rate of 100%). Three patients experienced relapse, two of whom re-entered partial remission after resuming daratumumab therapy. Proteinuria declined significantly, from a median of 4346 mg\/d to 1264 mg\/d by 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daratumumab demonstrated an acceptable safety profile and resulted in significant improvement in proteinuria while stabilizing kidney function in patients with PGNMID, suggesting the drug merits further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number:<\/jats:title>\n                    <jats:p>Daratumumab in Treatment of PGNMID and C3 GN, NCT03095118<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.2020101541","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T16:40:14Z","timestamp":1615221614000},"page":"1163-1173","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":83,"title":["Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits"],"prefix":"10.1681","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct03095118","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct03095118","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ladan","family":"Zand","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Hematology and Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-7709","authenticated-orcid":false,"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"El Ters","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"B1-20240826","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"B2-20240826","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"B3-20240826","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2009010110","article-title":"Proliferative glomerulonephritis with monoclonal IgG deposits","volume":"20","author":"Nasr","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B4-20240826","doi-asserted-by":"crossref","first-page":"770","DOI":"10.2215\/CJN.06760909","article-title":"Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy","volume":"5","author":"Sethi","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20240826","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mayocp.2015.01.024","article-title":"Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits","volume":"90","author":"Bhutani","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"B6-20240826","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2215\/CJN.06180710","article-title":"Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: A fortuitous association?","volume":"6","author":"Bridoux","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7-20240826","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: A case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B8-20240826","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","article-title":"Dense deposit disease associated with monoclonal gammopathy of undetermined significance","volume":"56","author":"Sethi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B9-20240826","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"key":"B10-20240826","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"key":"B11-20240826","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"B12-20240826","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.10611110","article-title":"Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: Correlation with IgG subclass and response to rituximab","volume":"6","author":"Guiard","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13-20240826","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5414\/CN109300","article-title":"High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy","volume":"89","author":"Lepori","year":"2018","journal-title":"Clin Nephrol"},{"key":"B14-20240826","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.01.028","article-title":"Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft","volume":"94","author":"Said","year":"2018","journal-title":"Kidney Int"},{"key":"B15-20240826","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MNH.0000000000000201","article-title":"Spectrum of manifestations of monoclonal gammopathy-associated renal lesions","volume":"25","author":"Sethi","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B16-20240826","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B17-20240826","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"B18-20240826","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"B19-20240826","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"B20-20240826","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B22-20240826","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B24-20240826","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B25-20240826","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"B26-20240826","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B27-20240826","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40262-016-0477-1","article-title":"Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment","volume":"56","author":"Clemens","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B28-20240826","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1097\/IJG.0000000000001562","article-title":"Bilateral secondary angle closure during daratumumab infusion: A case report and review of the literature","volume":"29","author":"Edwards","year":"2020","journal-title":"J Glaucoma"},{"key":"B29-20240826","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/IJG.0000000000000995","article-title":"Bilateral angle closure following the infusion of a monoclonal antibody to treat relapsing multiple myeloma","volume":"27","author":"Lee","year":"2018","journal-title":"J Glaucoma"},{"key":"B30-20240826","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-8993(98)01347-X","article-title":"Characterization and localization of CD38 in the vertebrate eye","volume":"821","author":"Khoo","year":"1999","journal-title":"Brain Res"},{"key":"B31-20240826","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajoc.2018.12.017","article-title":"Daratumumab-induced transient myopic shift","volume":"13","author":"Mavrommatis","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B32-20240826","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","article-title":"Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H","volume":"163","author":"Jokiranta","year":"1999","journal-title":"J Immunol"},{"key":"B33-20240826","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(86)92192-6","article-title":"Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis","volume":"2","author":"Winearls","year":"1986","journal-title":"Lancet"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020101541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:29:48Z","timestamp":1786130988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020101541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2020101541","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2020-10-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}